1
|
Lewis KD, Peris K, Sekulic A, Stratigos AJ, Dunn L, Eroglu Z, Chang ALS, Migden MR, Yoo SY, Mohan K, Coates E, Okoye E, Bowler T, Baurain JF, Bechter O, Hauschild A, Butler MO, Hernandez-Aya L, Licitra L, Neves RI, Ruiz ES, Seebach F, Lowy I, Goncalves P, Fury MG. Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors. Ann Oncol 2024; 35:221-228. [PMID: 38072158 DOI: 10.1016/j.annonc.2023.10.123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2023] [Revised: 10/06/2023] [Accepted: 10/10/2023] [Indexed: 01/19/2024] Open
Abstract
BACKGROUND Metastatic basal cell carcinoma (mBCC) is a rare condition with no effective second-line treatment options. Cemiplimab is an immune checkpoint inhibitor that blocks the binding of programmed cell death-1 (PD-1) to its ligands, programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2). Here, we present the final analysis of cemiplimab in patients with mBCC after first-line hedgehog pathway inhibitor (HHI) treatment (NCT03132636). PATIENTS AND METHODS In this open-label, single-arm, phase II study, adults with mBCC and Eastern Cooperative Oncology Group performance status ≤1, post-HHI treatment, received cemiplimab 350 mg intravenously every 3 weeks for ≤93 weeks or until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) by independent central review (ICR). Duration of response (DOR) was a key secondary endpoint. Other secondary endpoints were ORR per investigator assessment, progression-free survival (PFS), overall survival (OS), complete response rate, safety, and tolerability. RESULTS Fifty-four patients were enrolled: 70% were male and the median age of patients was 64 [interquartile range (IQR) 57.0-73.0] years. The median duration of follow-up was 8 months (IQR 4-21 months). The ORR per ICR was 22% [95% confidence interval (CI) 12% to 36%], with 2 complete responses and 10 partial responses. Among responders, the median time to response per ICR was 3 months (IQR 2-7 months). The estimated median DOR per ICR was not reached [95% CI 10 months-not evaluable (NE)]. The disease control rate was 63% (95% CI 49% to 76%) per ICR and 70% (95% CI 56% to 82%) per investigator assessment. The median PFS per ICR was 10 months (95% CI 4-16 months); the median OS was 50 months (95% CI 28 months-NE). The most common treatment-emergent adverse events were fatigue [23 (43%)] and diarrhoea [20 (37%)]. There were no treatment-related deaths. CONCLUSIONS Cemiplimab demonstrated clinically meaningful antitumour activity, including durable responses, and an acceptable safety profile in patients with mBCC who had disease progression on or intolerance to HHI therapy.
Collapse
Affiliation(s)
- K D Lewis
- Department of Medicine-Medical Oncology, University of Colorado School of Medicine, Aurora, USA.
| | - K Peris
- Department of Medicine and Translational Surgery, Dermatology, Università Cattolica del Sacro Cuore, Rome; Department of Medical and Surgical Sciences, Dermatology, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy
| | - A Sekulic
- Department of Dermatology, Mayo Clinic, Scottsdale, USA
| | - A J Stratigos
- First Department of Dermatology-Venereology, National and Kapodistrian University of Athens, Andreas Sygros Hospital, Athens, Greece
| | - L Dunn
- Department of Medicine, Head and Neck Medical Oncology, Memorial Sloan Kettering Cancer Center, New York
| | - Z Eroglu
- Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa
| | - A L S Chang
- Dermatology Department, Stanford University School of Medicine, Redwood City
| | - M R Migden
- Department of Dermatology and Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston; Department of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston
| | - S-Y Yoo
- Regeneron Pharmaceuticals, Inc., Tarrytown, USA
| | - K Mohan
- Regeneron Pharmaceuticals, Inc., Tarrytown, USA
| | - E Coates
- Regeneron Pharmaceuticals, Inc., Tarrytown, USA
| | - E Okoye
- Regeneron Pharmaceuticals, Inc., Tarrytown, USA
| | - T Bowler
- Regeneron Pharmaceuticals, Inc., Tarrytown, USA
| | - J-F Baurain
- Department of Medical Oncology, Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels
| | - O Bechter
- Department of General Medical Oncology, University Hospitals, Leuven, Belgium
| | - A Hauschild
- Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Kiel, Germany
| | - M O Butler
- Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada
| | - L Hernandez-Aya
- Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, St Louis, USA
| | - L Licitra
- Department of Medical Oncology Head and Neck Cancer, Istituto Nazionale dei Tumori, Milan; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| | - R I Neves
- Division of Plastic Surgery, Penn State Milton S. Hershey Medical Center, Hershey
| | - E S Ruiz
- Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, USA
| | - F Seebach
- Regeneron Pharmaceuticals, Inc., Tarrytown, USA
| | - I Lowy
- Regeneron Pharmaceuticals, Inc., Tarrytown, USA
| | - P Goncalves
- Regeneron Pharmaceuticals, Inc., Tarrytown, USA
| | - M G Fury
- Regeneron Pharmaceuticals, Inc., Tarrytown, USA
| |
Collapse
|
2
|
Makharadze T, Gogishvili M, Melkadze T, Baramidze A, Giorgadze D, Penkov K, Laktionov K, Nemsadze G, Nechaeva M, Rozhkova I, Kalinka E, Li S, Li Y, Kaul M, Pouliot JF, Seebach F, Lowy I, Gullo G, Rietschel P. 50 Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: Longer follow-up results from the phase III EMPOWER-Lung 3 trial. J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00259-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/03/2023]
|
3
|
Kilickap S, Özgüroğlu M, Sezer A, Gumus M, Bondarenko I, Gogishvili M, Türk H, Cicin I, Bentsion D, Gladkov O, Clingan P, Sriuranpong V, He X, Pouliot JF, Seebach F, Lowy I, Gullo G, Rietschel P. 10MO EMPOWER-Lung 1: Cemiplimab (CEMI) monotherapy as first-line (1L) treatment of patients (pts) with brain metastases from advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50% — 3-year update. J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00264-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/04/2023]
|
4
|
Kalinka E, Bondarenko I, Gogishvili M, Melkadze T, Baramidze A, Sezer A, Makharadze T, Kilickap S, Gumus M, Penkov K, Giorgadze D, Özgüroğlu M, He X, Pouliot JF, Seebach F, Lowy I, Gullo G, Rietschel P. 114M0 First-line cemiplimab for locally advanced non-small cell lung cancer: Updated subgroup analyses from EMPOWER-Lung 1 and EMPOWER-Lung 3. J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00369-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/04/2023]
|
5
|
Garassino M, Kilickap S, Özgüroğlu M, Sezer A, Gumus M, Bondarenko I, Gogishvili M, Nechaeva M, Schenker M, Cicin I, Fuang H, Kulyaba Y, Dvorkin M, Zyuhal K, Scheusan RI, He X, Kaul M, Okoye E, Li Y, Li S, Pouliot JF, Seebach F, Lowy I, Gullo G, Rietschel P. OA01.05 Three-year Outcomes per PD-L1 Status and Continued Cemiplimab Beyond Progression + Chemotherapy: EMPOWER-Lung 1. J Thorac Oncol 2023. [DOI: 10.1016/j.jtho.2022.09.122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
|
6
|
Cho B, Dy G, Kim T, Sarker D, Hamid O, Williamson S, Sang-We K, Hatim H, Chen S, Mani J, Jankovic V, Paccaly A, Masinde S, Lowy I, Brennan L, Gullo G. 127P Phase I study of fianlimab: A human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced NSCLC. Immuno-Oncology and Technology 2022. [DOI: 10.1016/j.iotech.2022.100239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
7
|
Moore K, Bouberhan S, Hamilton E, Liu J, O'Cearbhaill R, O'Malley D, Papadimitriou K, Schröder D, Van Nieuwenhuysen E, Yoo SY, Peterman M, Goncalves P, Schmidt T, Zhu M, Lowy I, Uldrick T, Miller E. 197TiP First-in-human (FIH) phase I/II study of ubamatamab, a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer (OC). Immuno-Oncology and Technology 2022. [DOI: 10.1016/j.iotech.2022.100309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
8
|
Baramidze A, Gessner C, Gogishvili M, Sezer A, Makharadze T, Kilickap S, Gumus M, Tewari K, Monk B, de Melo A, Oaknin A, Li S, Gao B, Mathias M, Gullo G, Salvati M, Seebach F, Lowy I, Fury M, Rietschel P. 168P Liver metastases (mets) and treatment effect of cemiplimab-based therapy: An analysis from three phase III trials (EMPOWER-Lung 1, EMPOWER-Lung 3 part 2, and EMPOWER-Cervical 1). Immuno-Oncology and Technology 2022. [DOI: 10.1016/j.iotech.2022.100280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
9
|
Hamid O, Weise A, Kim T, Mckean M, Lakhani N, Crown J, Kaczmar J, Papadopoulos K, Chen S, Mani J, Jankovic V, Kroog G, Sims T, Lowy I, Gullo G. 400P Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022] Open
|
10
|
Ho G, Ozguroglu M, Kilickap S, Sezer A, Gumus M, Bondarenko I, Gogishvili M, Nechaeva M, Schenker M, Cicin I, Kulyaba Y, Dvorkin M, Zyuhal K, Scheusan R, Li S, Pouliot JF, Seebach F, Lowy I, Gullo G, Rietschel P. 327P Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-lung 1 trial. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.366] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022] Open
|
11
|
Rischin D, Brungs D, Day F, Christie H, Patel V, Adams G, Jackson J, Schurmann M, Kirtbaya D, Shin T, Hart C, Stankevich E, Li S, Lowy I, Han H, Fury M, Porceddu S. C-POST Protocol Update: A Phase 3, Randomized, Double-Blind Study of Adjuvant Cemiplimab vs. Placebo Post Surgery and Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.1822] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
12
|
Migden M, Schmults C, Khushanlani N, Guminski A, Chang A, Lewis K, Ansstas G, Bowyer S, Hughes B, Schadendorf D, Modi B, Dunn L, Flatz L, Hauschild A, Yoo SY, Booth J, Seebach F, Lowy I, Fury M, Rischin D. 814P Phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 groups 1, 2 and 3. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.940] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
13
|
Kerr K, Perez J, McGuire K, Baker B, Fang F, Li J, Wlasiuk G, Li S, Gao B, Pouliot JF, Seebach F, Lowy I, Gullo G, Rietschel P. 114P Clinical interchangeability of programmed cell death-ligand 1 (PD-L1) immunohistochemistry (IHC) assays for the treatment of first-line (1L) non-small cell lung cancer (NSCLC) with cemiplimab. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
14
|
Hughes B, Grob J, Bowyer S, Day F, Ladwa R, Stein B, Muñoz Couselo E, Basset-Seguin N, Guminski A, Mortier L, Hauschild A, Migden M, Schmults C, Yoo SY, Booth J, Seebach F, Lowy I, Fury M, Rischin D. 818P Phase II confirmatory study of cemiplimab (350mg IV Q3W) in patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Study 1540 Group 6. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.944] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
15
|
Hamid O, Weise A, Kim T, Mckean M, Lakhani N, Kaczmar J, Papadopoulos K, Chen S, Mani J, Jankovic V, Kroog G, Sims T, Lowy I, Gullo G. 790MO Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.916] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
16
|
Kalinka-Warzocha E, Gogishvili M, Makharadze T, Dvorkin M, Penkov K, Laktionov K, Nechaeva M, Rozhkova I, He X, Quek R, Pouliot JF, Seebach F, Lowy I, Gullo G, Rietschel P. 954P Cemiplimab with platinum-based chemotherapy (chemo) for first-line (1L) locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 3 subgroup analysis. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
17
|
Brouwer‐Visser J, Fiaschi N, Deering RP, Dhanik A, Cygan KJ, Zhang W, Jeong S, Pourpe S, Boucher L, Hamon S, Topp MS, Bannerji R, Duell J, Advani RH, Flink DM, Chaudhry A, Sirulnik A, Lowy I, Murphy AJ, Weinreich DM, Yancopoulos GD, Thurston G, Ambati SR, Jankovic V. CLINICAL RESPONSES TO ODRONEXTAMAB (REGN1979): CORRELATION WITH LOSS OF CD20 EXPRESSION AS A POTENTIAL MECHANISM OF RESISTANCE AND BASELINE BIOMARKERS OF TUMOR T CELLS. Hematol Oncol 2021. [DOI: 10.1002/hon.6_2880] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- J Brouwer‐Visser
- Regeneron Pharmaceuticals, Inc Precision Medicine Tarrytown New York USA
| | - N Fiaschi
- Regeneron Pharmaceuticals, Inc Oncology and Angiogenesis Tarrytown New York USA
| | - R. P Deering
- Regeneron Pharmaceuticals, Inc Oncology and Angiogenesis Tarrytown New York USA
| | - A Dhanik
- Regeneron Pharmaceuticals, Inc VI Next Tarrytown New York USA
| | - K. J Cygan
- Regeneron Pharmaceuticals, Inc VI Next Tarrytown New York USA
| | - W Zhang
- Regeneron Pharmaceuticals, Inc Molecular Profiling and Data Science Tarrytown New York USA
| | - S Jeong
- Regeneron Pharmaceuticals, Inc Oncology and Angiogenesis Tarrytown New York USA
| | - S Pourpe
- Regeneron Pharmaceuticals, Inc Oncology and Angiogenesis Tarrytown New York USA
| | - L Boucher
- Regeneron Pharmaceuticals, Inc Oncology and Angiogenesis Tarrytown New York USA
| | - S Hamon
- Regeneron Pharmaceuticals, Inc Precision Medicine Tarrytown New York USA
| | | | - R Bannerji
- Rutgers Cancer Institute of New Jersey Division of Blood Disorders New Brunswick New Jersey USA
| | - J Duell
- Universitätsklinikum Würzburg Department of Internal Medicine 2 Würzburg Germany
| | - R. H Advani
- Stanford University Department of Medicine Stanford California USA
| | - D. M Flink
- Regeneron Pharmaceuticals, Inc Global Development Tarrytown New York USA
| | - A Chaudhry
- Regeneron Pharmaceuticals, Inc Hematology Tarrytown New York USA
| | - A Sirulnik
- Regeneron Pharmaceuticals, Inc Global Clinical Development Tarrytown New York USA
| | - I Lowy
- Regeneron Pharmaceuticals, Inc Translation Science and Oncology Tarrytown New York USA
| | - A. J Murphy
- Regeneron Pharmaceuticals, Inc Research Tarrytown New York USA
| | - D. M Weinreich
- Regeneron Pharmaceuticals, Inc Head of Global Clinical Development Tarrytown New York USA
| | - G. D Yancopoulos
- Regeneron Pharmaceuticals, Inc Chief Scientific Officer Tarrytown New York USA
| | - G Thurston
- Regeneron Pharmaceuticals, Inc Oncology Research Tarrytown New York USA
| | - S. R Ambati
- Regeneron Pharmaceuticals, Inc Clinical Sciences Hematology Tarrytown New York USA
| | - V Jankovic
- Regeneron Pharmaceuticals, Inc Precision Medicine Tarrytown New York USA
| |
Collapse
|
18
|
Kilickap S, Sezer A, Gümüş M, Bondarenko I, Özgüroğlu M, Gogishvili M, Turk H, Cicin I, Bentsion D, Gladkov O, Clingan P, Sriuranpong V, Rizvi N, Li S, Lee S, Makharadze T, Paydas S, Nechaeva M, Seebach F, Weinreich D, Yancopoulos G, Gullo G, Lowy I, Rietschel P. OA01.03 Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
19
|
Sezer A, Kilickap S, Gümüş M, Bondarenko I, Özgüroğlu M, Gogishvili M, Turk H, Çiçin İ, Bentsion D, Gladkov O, Clingan P, Sriuranpong V, Rizvi N, Li S, Lee S, Gullo G, Lowy I, Rietschel P. 378MO EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.372] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
20
|
Sezer A, Kilickap S, Gümüş M, Bondarenko I, Özgüroğlu M, Gogishvili M, Turk H, Çiçin İ, Bentsion D, Gladkov O, Clingan P, Sriuranpong V, Rizvi N, Li S, Lee S, Gullo G, Lowy I, Rietschel P. LBA52 EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.2285] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
21
|
Shim B, Lee S, de Castro Carpeño J, Chiu CH, Cobo M, Kim H, Ryu J, Tarruella M, Summers Y, Thomas C, Xu Y, Lowy I, Rietschel P. 1269P EMPOWER-lung 4: Phase II, randomized, open-label high dose or standard dose cemiplimab alone/plus ipilimumab in the second-line treatment of advanced non-small cell lung cancer (NSCLC). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1583] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
22
|
Rischin D, Khushalani N, Schmults C, Guminski A, Chang A, Lewis K, Lim A, Hernandez-Aya L, Hughes B, Schadendorf D, Hauschild A, Stankevich E, Booth J, Li S, Chen Z, Desai J, Lowy I, Fury M, Migden M. Impact of Prior Lines of Systemic Therapy (PST) on the Efficacy Of Cemiplimab, a Human Monoclonal Anti–PD-1, in Patients (PTS) with Advanced Cutaneous Squamous Cell Carcinoma (CSCC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz451.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
23
|
Rischin D, Lim A, Schmults C, Khushalani N, Hughes B, Schadendorf D, Dunn L, Chang A, Hauschild A, Ulrich C, Eigentler T, Migden M, Pavlick A, Geiger J, Stankevich E, Li S, Lowy I, Fury M, Guminski A. Phase II study of 2 dosing regimens of cemiplimab, a human monoclonal anti–PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz255.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
24
|
Marron T, Wolf A, Flores R, Veluswamy R, Gomez J, Beasley M, Yankelevitz D, Leader A, Lowy I, Miller E, Thurston G, Jankovic V, Deering R, Brown B, Rahman A, Gnjatic S, Hirsch F, Bhardwaj N, Merad M. EP1.04-15 NSCLC Response Determinants to Chemoimmunotherapy: Deep Profiling of Tumors Following Neoadjuvant Cemiplimab and Chemotherapy. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.2143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
25
|
Migden M, Paccaly A, Papadopoulos K, Yang F, Davis J, Rippley R, Lowy I, Fury M, Stankevich E, Rischin D. Pharmacokinetic (PK) analysis of weight-based and fixed dose cemiplimab in patients (pts) with advanced malignancies. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz253.104] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
26
|
Rischin D, Fury M, Lowy I, Stankevich E, Li S, Han H, Porceddu S. A phase III, randomised, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation in patients with high-risk cutaneous squamous cell carcinoma (CSCC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz255.060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
Gogishvili M, Mobashery N, Makharadze T, Navarro M, Snodgrass P, Chen H, Lowy I, Rietschel P, Lee S. P2.01-26 EMPOWER-Lung 3: Phase 3 Study of Combinations of Cemiplimab and Chemotherapy in First-Line Treatment of Advanced NSCLC. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1370] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
28
|
Sezer A, Gogishvili M, Bentsion D, Kilickap S, Lowczak A, Gumus M, Gladkov O, Clingan P, Sriuranpong V, Rizvi N, Lee S, Li S, Snodgrass P, Navarro M, Lowy I, Rietschel P. P2.01-01 Cemiplimab, a Human PD-1 Monoclonal Antibody, Versus Chemotherapy in First-Line Treatment of Advanced NSCLC with PD-L1 ≥50%. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1345] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
29
|
Topp M, Arnason J, Advani R, Brown J, Allan J, Ansell S, O'Brien S, Chavez J, Duell J, Rosenwald A, Charnas R, Ambati S, Adriaens L, Ufkin M, Zhu M, Li J, Gasparini P, Jankovic V, Fiaschi N, Zhang W, Hamon S, Thurston G, Murphy A, Yancopoulos G, Lowy I, Sternberg D, Bannerji R. CLINICAL ACTIVITY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY (AB) IN PATIENTS (PTS) WITH (W/) RELAPSED/REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL). Hematol Oncol 2019. [DOI: 10.1002/hon.58_2629] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- M.S. Topp
- Department of Internal Medicine; Universitätsklinikum Würzburg; Würzburg Germany
| | - J. Arnason
- Hematology/Oncology Division; Beth Israel Deaconess Medical Center; Boston United States
| | - R. Advani
- Department of Medicine; Stanford University; Stanford United States
| | - J.R. Brown
- Center for Hematologic Oncology; Dana-Farber Cancer Institute; Boston United States
| | - J. Allan
- Division of Hematology and Medical Oncology; Weill Cornell Medicine; New York United States
| | - S. Ansell
- Department of Internal Medicine; Mayo Clinic; Rochester United States
| | - S. O'Brien
- Division of Hematology/Oncology; University of California; Irvine United States
| | - J. Chavez
- Department of Oncologic Sciences; Moffitt Cancer Center; Tampa United States
| | - J. Duell
- Department of Internal Medicine; Universitätsklinikum Würzburg; Würzburg Germany
| | - A. Rosenwald
- Institute of Pathology; University of Würzburg; Würzburg Germany
| | - R. Charnas
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - S.R. Ambati
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - L. Adriaens
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Basking Ridge United States
| | - M. Ufkin
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - M. Zhu
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - J. Li
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Basking Ridge United States
| | - P. Gasparini
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - V. Jankovic
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - N. Fiaschi
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - W. Zhang
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - S. Hamon
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - G. Thurston
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - A.J. Murphy
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - G.D. Yancopoulos
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - I. Lowy
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - D. Sternberg
- Hematology/Oncology; Regeneron Pharmaceuticals, Inc.; Tarrytown United States
| | - R. Bannerji
- Section of Hematologic Malignancies; Rutgers Cancer Institute of New Jersey; New Brunswick United States
| |
Collapse
|
30
|
Moreno V, Gil-Martin M, Johnson M, Aljumaily R, Lopez Criado P, Northfelt D, Crittenden M, Jabbour S, Rosen L, Garrido P, Hervás Morón A, Rietschel P, Mohan K, Li J, Stankevich E, Feng M, Lowy I, Fury M. Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy487.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
31
|
Babiker H, Brana I, Mahadevan D, Owonikoko T, Calvo E, Rischin D, Moreno V, Papadopoulos K, Crittenden M, Formenti S, Giralt J, Garrido P, Hervás Morón A, Mohan K, Fury M, Lowy I, Stankevich E, Feng M, Li J, Mathias M. Phase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy487.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
32
|
Owonikoko T, Papadopoulos K, Johnson M, Gil Martín M, Moreno V, Salama A, Calvo E, Yee N, Safran H, Aljumaily R, Mahadevan D, Niu J, Kal Mohan K, Li J, Stankevich E, Mathias M, Lowy I, Fury M, Babiker H. Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy487.002] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
33
|
Rischin D, Gil-Martin M, González-Martin A, Brana I, Hou J, Cho D, Falchook G, Formenti S, Jabbour S, Moore K, Naing A, Papadopoulos K, Baranda J, Weise A, Fury M, Feng M, Li J, Lowy I, Mathias M. Cemiplimab, a human PD-1 monoclonal antibody, in patients (pts) with recurrent or metastatic cervical cancer: Interim data from phase I cohorts. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy487.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
34
|
He A, Weiss G, Falchook G, Yee N, Gil-Martin M, Shahda S, Moreno V, Brana I, Crittenden M, Formenti S, Al-Rajabi R, Papadopoulos K, Pishvaian M, Stankevich E, Feng M, Li J, Mathias M, Kroog G, Lowy I, Fury M. Cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort (EC) in a phase I study. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy487.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
35
|
Tewari K, Vergote I, Oaknin A, Alvarez E, Gaillard S, Lheureux S, Rischin D, Santin A, Feng M, Mathias M, Fury M, Lowy I, Monk B. GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥ second-line recurrent or metastatic cervical cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy436.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
36
|
Babiker H, Brana I, Mahadevan D, Owonikoko T, Calvo E, Rischin D, Moreno V, Papadopoulos K, Crittenden M, Formenti S, Giralt J, Garrido Lopez P, Hervás Morón A, Mohan K, Fury M, Lowy I, Stankevich E, Feng M, Li J, Mathias M. Phase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy288.044] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
37
|
Moreno V, Gil-Martin M, Johnson M, Aljumaily R, Lopez Criado P, Northfelt D, Crittenden M, Jabbour S, Rosen L, Garrido Lopez P, Hervás Morón A, Rietschel P, Mohan K, Li J, Stankevich E, Rowlands T, Feng M, Lowy I, Fury M. Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy288.035] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
38
|
Rischin D, Gil-Martin M, González-Martín A, Brana I, Hou J, Cho D, Falchook G, Formenti S, Jabbour S, Moore K, Naing A, Papadopoulos K, Baranda J, Weise A, Fury M, Feng M, Li J, Lowy I, Mathias M. Cemiplimab, a human PD-1 monoclonal antibody, in patients (pts) with recurrent or metastatic cervical cancer: Interim data from phase I cohorts. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy285.166] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
39
|
Owonikoko T, Papadopoulos K, Gil-Martin M, Moreno V, Salama A, Calvo E, Safran H, González-Martín A, Aljumaily R, Mahadevan D, Niu J, Kal Mohan K, Li J, Stankevich E, Mathias M, Lowy I, Fury M, Babiker H. Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy289.048] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
40
|
Pishvaian M, Weiss G, Falchook G, Yee N, Gil-Martin M, Shahda S, Moreno V, Brana I, Crittenden M, Formenti S, Al-Rajabi R, Papadopoulos K, Stankevich E, Feng M, Li J, Mathias M, Kroog G, Lowy I, Fury M. Cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort in a phase I study. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy288.024] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
41
|
Moreno V, Gil-Martin M, Johnson M, Aljumaily R, Lopez-Criado M, Northfelt D, Crittenden M, Jabbour S, Rosen L, Calvo E, Papadopoulos K, Garrido P, Hervás Morón A, Rietschel P, Mohan K, Li J, Stankevich E, Feng M, Lowy I, Fury M. MA04.01 Cemiplimab, a Human Monoclonal Anti-PD-1, Alone or in Combination with Radiotherapy: Phase 1 NSCLC Expansion Cohorts. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.340] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
42
|
Gerritsen W, Santegoets S, Stam A, Hege K, Versluis J, Sacks N, Lowy I, Harding T, van den Eertwegh A, De Gruijl T. Biomarkers for Clinical Outcome of Combined Immunotherapy with Granulocyte-Macrophage Colony-Stimulating Factor-Tranduced Allogeneic Prostate Cancer Cells (GVAX) and Ipilimumab in Castration-Resistant Prostate Cancer Patients (CRPC). Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33473-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
43
|
Sznol M, Powderly JD, Smith DC, Brahmer JR, Drake CG, McDermott DF, Lawrence DP, Wolchok JD, Topalian SL, Lowy I. Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.2506] [Citation(s) in RCA: 57] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
44
|
Slovin SF, Beer TM, Higano CS, Tejwani S, Hamid O, Picus J, Harzstark A, Scher HI, Lan Z, Lowy I. Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.5138] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5138 Background: IPI is a fully human, monoclonal anti-CTLA-4 antibody capable of enhancing anti-tumor immunity. In preclinical models, XRT releases tumor antigens and enhances anti-tumor activity of CTLA-4 blockade. In the dose escalation part of this Phase I/II trial 10 mg/kg dosing of IPI with or without prior priming by single fraction XRT was feasible. We now report initial phase II results. Methods: 45 patients (pts) with mCRPC and ECOG PS of 0–1 received 10 mg/kg q3 weeks (wks) X 4 of IPI in 3 groups: (1) IPI alone n=16, (2) IPI + XRT n=15 chemotherapy naïve (NoCHEMO), and (3) IPI + XRT n=14 chemotherapy experienced (CHEMO) pts. XRT (800 cGy) was given to up to 3 involved bony sites (GI tract sparing) just prior to starting IPI. PSA was monitored monthly, with scans q 3 months. Endpoints were to confirm safety and an initial assessment of activity. Results: 17 pts (38%) experienced 26 immune-related adverse events (irAEs) including diarrhea/colitis (12), rash/pruritus (6), hepatitis (4), endocrinopathy (4). 11 pts (24%) experienced 13 ≥ Grade 3 irAEs: GI (9; 20%) and hepatitis (4; 9%); all resolved with immunosuppression. 10 of 45 pts (22%; 95% CI 10–34%) had confirmed PSA declines ≥ 50% as follows in the table below. Median time to PSA decline was 5.7 wks (r 3 to 21 wks); median duration 23 wks (r 3 to 84+ wks). In one pt dosed with IPI alone, PSA ≤ 0.05 ng/ml, as well as a CR of bone, nodal and prostate lesions continue for 54+ and 84+ wks, respectively. Conclusions: irAEs in the 10 mg/kg cohorts are similar in type and rate to IPI in melanoma. irAEs and PSA declines occurred in chemotherapy naïve and post chemotherapy patients, and with or without XRT. Addition of XRT to 10 mg/kg is well tolerated. Time to response can be delayed, with a durable median response of 23 wks. Further study of IPI in mCRPC is warranted, with or without XRT as a potential immunosupportive maneuver to augment clinical responses to IPI. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- S. F. Slovin
- Memorial Sloan-Kettering Cancer Center, New York, NY; Oregon Health & Science University, Portland, OR; University of Washington School of Medicine, Seattle, WA; Henry Ford Health System, Detroit, MI; The Angeles Clinic and Research Institute, Santa Monica, CA; Washington University School of Medicine, St. Louis, MO; UCSF School of Medicine, San Francisco, CA; Medarex, Inc., Bloomsbury, NJ
| | - T. M. Beer
- Memorial Sloan-Kettering Cancer Center, New York, NY; Oregon Health & Science University, Portland, OR; University of Washington School of Medicine, Seattle, WA; Henry Ford Health System, Detroit, MI; The Angeles Clinic and Research Institute, Santa Monica, CA; Washington University School of Medicine, St. Louis, MO; UCSF School of Medicine, San Francisco, CA; Medarex, Inc., Bloomsbury, NJ
| | - C. S. Higano
- Memorial Sloan-Kettering Cancer Center, New York, NY; Oregon Health & Science University, Portland, OR; University of Washington School of Medicine, Seattle, WA; Henry Ford Health System, Detroit, MI; The Angeles Clinic and Research Institute, Santa Monica, CA; Washington University School of Medicine, St. Louis, MO; UCSF School of Medicine, San Francisco, CA; Medarex, Inc., Bloomsbury, NJ
| | - S. Tejwani
- Memorial Sloan-Kettering Cancer Center, New York, NY; Oregon Health & Science University, Portland, OR; University of Washington School of Medicine, Seattle, WA; Henry Ford Health System, Detroit, MI; The Angeles Clinic and Research Institute, Santa Monica, CA; Washington University School of Medicine, St. Louis, MO; UCSF School of Medicine, San Francisco, CA; Medarex, Inc., Bloomsbury, NJ
| | - O. Hamid
- Memorial Sloan-Kettering Cancer Center, New York, NY; Oregon Health & Science University, Portland, OR; University of Washington School of Medicine, Seattle, WA; Henry Ford Health System, Detroit, MI; The Angeles Clinic and Research Institute, Santa Monica, CA; Washington University School of Medicine, St. Louis, MO; UCSF School of Medicine, San Francisco, CA; Medarex, Inc., Bloomsbury, NJ
| | - J. Picus
- Memorial Sloan-Kettering Cancer Center, New York, NY; Oregon Health & Science University, Portland, OR; University of Washington School of Medicine, Seattle, WA; Henry Ford Health System, Detroit, MI; The Angeles Clinic and Research Institute, Santa Monica, CA; Washington University School of Medicine, St. Louis, MO; UCSF School of Medicine, San Francisco, CA; Medarex, Inc., Bloomsbury, NJ
| | - A. Harzstark
- Memorial Sloan-Kettering Cancer Center, New York, NY; Oregon Health & Science University, Portland, OR; University of Washington School of Medicine, Seattle, WA; Henry Ford Health System, Detroit, MI; The Angeles Clinic and Research Institute, Santa Monica, CA; Washington University School of Medicine, St. Louis, MO; UCSF School of Medicine, San Francisco, CA; Medarex, Inc., Bloomsbury, NJ
| | - H. I. Scher
- Memorial Sloan-Kettering Cancer Center, New York, NY; Oregon Health & Science University, Portland, OR; University of Washington School of Medicine, Seattle, WA; Henry Ford Health System, Detroit, MI; The Angeles Clinic and Research Institute, Santa Monica, CA; Washington University School of Medicine, St. Louis, MO; UCSF School of Medicine, San Francisco, CA; Medarex, Inc., Bloomsbury, NJ
| | - Z. Lan
- Memorial Sloan-Kettering Cancer Center, New York, NY; Oregon Health & Science University, Portland, OR; University of Washington School of Medicine, Seattle, WA; Henry Ford Health System, Detroit, MI; The Angeles Clinic and Research Institute, Santa Monica, CA; Washington University School of Medicine, St. Louis, MO; UCSF School of Medicine, San Francisco, CA; Medarex, Inc., Bloomsbury, NJ
| | - I. Lowy
- Memorial Sloan-Kettering Cancer Center, New York, NY; Oregon Health & Science University, Portland, OR; University of Washington School of Medicine, Seattle, WA; Henry Ford Health System, Detroit, MI; The Angeles Clinic and Research Institute, Santa Monica, CA; Washington University School of Medicine, St. Louis, MO; UCSF School of Medicine, San Francisco, CA; Medarex, Inc., Bloomsbury, NJ
| | | |
Collapse
|
45
|
Brahmer JR, Topalian SL, Powderly J, Wollner I, Picus J, Drake CG, Stankevich E, Korman A, Pardoll D, Lowy I. Phase II experience with MDX-1106 (Ono-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.3018] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3018 Background: Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, may suppress antitumor immunity. This expansion cohort in a phase I/II trial of MDX-1106, a fully human IgG4 antibody blocking PD-1, sought to further evaluate the safety and activity of the 10 mg/kg dose. Other objectives included evaluation of pharmacokinetics (PK) and immunological effects. Methods: Patients (pts) with treatment refractory metastatic non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), colon cancer (CC), melanoma (MEL), or prostate cancer (CRPC), and no history of autoimmune disease received a single infusion of MDX-1106 at 10 mg/kg. Disease status was evaluated at week (wk) 8 by RECIST criteria. Pts with stable disease or lesional responses could receive additional MDX-1106 at wks 12 and 16. Those with PR/CR were observed without retreatment. Results: 21 pts (5 CC, 2 NSCLC, 8 MEL, 5 HRPC, 1 RCC) were treated from 10/07 to present, and 6 were retreated. No MDX-1106 related SAEs occurred. One pt developed arthritic symptoms requiring treatment, and 2 pts had asymptomatic TSH elevation. One pt with RCC had a PR after 3 doses, lasting 5+ months (mo). Lesional regressions (“mixed response”) were seen in 2 MEL pts; to date, one has received 7 doses of MDX-1106 over 15 mo without serious toxicity. Biopsy of a regressing MEL lymph node metastasis showed a moderately increased and selective CD8+ T cell infiltrate post treatment. The median serum t 1/2 of MDX-1106 was 20.6 days, which was roughly 50% longer than observed for lower doses. There was no evidence of immunogenicity based on HAHA development. Interestingly, in contrast to PK results, flow cytometric analysis demonstrated sustained occupancy of 60–80% PD-1 molecules on T cells for at least 3 mo following a single dose. Analyses of circulating lymphocyte subsets and tumor B7-H1 expression are in progress. Conclusions: Intermittent dosing of MDX-1106 at 10 mg/kg demonstrated clinical activity against RCC and MEL without serious toxicity. Therapy with MDX-1106 to enhance endogenous antitumor immunity, either alone or combined with other immunological therapies, warrants further study. [Table: see text]
Collapse
Affiliation(s)
- J. R. Brahmer
- SKCCC at Johns Hopkins, Baltimore, MD; Carolina BioOncology Institute, Huntersville, NC; Henry Ford Hospital, Detroit, MI; Washington University Siteman Cancer Center, St. Louis, MO; Medarex, Inc., Bloomsbury, NJ
| | - S. L. Topalian
- SKCCC at Johns Hopkins, Baltimore, MD; Carolina BioOncology Institute, Huntersville, NC; Henry Ford Hospital, Detroit, MI; Washington University Siteman Cancer Center, St. Louis, MO; Medarex, Inc., Bloomsbury, NJ
| | - J. Powderly
- SKCCC at Johns Hopkins, Baltimore, MD; Carolina BioOncology Institute, Huntersville, NC; Henry Ford Hospital, Detroit, MI; Washington University Siteman Cancer Center, St. Louis, MO; Medarex, Inc., Bloomsbury, NJ
| | - I. Wollner
- SKCCC at Johns Hopkins, Baltimore, MD; Carolina BioOncology Institute, Huntersville, NC; Henry Ford Hospital, Detroit, MI; Washington University Siteman Cancer Center, St. Louis, MO; Medarex, Inc., Bloomsbury, NJ
| | - J. Picus
- SKCCC at Johns Hopkins, Baltimore, MD; Carolina BioOncology Institute, Huntersville, NC; Henry Ford Hospital, Detroit, MI; Washington University Siteman Cancer Center, St. Louis, MO; Medarex, Inc., Bloomsbury, NJ
| | - C. G. Drake
- SKCCC at Johns Hopkins, Baltimore, MD; Carolina BioOncology Institute, Huntersville, NC; Henry Ford Hospital, Detroit, MI; Washington University Siteman Cancer Center, St. Louis, MO; Medarex, Inc., Bloomsbury, NJ
| | - E. Stankevich
- SKCCC at Johns Hopkins, Baltimore, MD; Carolina BioOncology Institute, Huntersville, NC; Henry Ford Hospital, Detroit, MI; Washington University Siteman Cancer Center, St. Louis, MO; Medarex, Inc., Bloomsbury, NJ
| | - A. Korman
- SKCCC at Johns Hopkins, Baltimore, MD; Carolina BioOncology Institute, Huntersville, NC; Henry Ford Hospital, Detroit, MI; Washington University Siteman Cancer Center, St. Louis, MO; Medarex, Inc., Bloomsbury, NJ
| | - D. Pardoll
- SKCCC at Johns Hopkins, Baltimore, MD; Carolina BioOncology Institute, Huntersville, NC; Henry Ford Hospital, Detroit, MI; Washington University Siteman Cancer Center, St. Louis, MO; Medarex, Inc., Bloomsbury, NJ
| | - I. Lowy
- SKCCC at Johns Hopkins, Baltimore, MD; Carolina BioOncology Institute, Huntersville, NC; Henry Ford Hospital, Detroit, MI; Washington University Siteman Cancer Center, St. Louis, MO; Medarex, Inc., Bloomsbury, NJ
| |
Collapse
|
46
|
Lin R, Yellin MJ, Lowy I, Safferman A, Chin K, Ibrahim R. An analysis of the effectiveness of specific guidelines for the management of ipilimumab-mediated diarrhea/colitis: Prevention of gastrointestinal perforation and/or colectomy. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.9063] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
47
|
Beer TM, Slovin SF, Higano CS, Tejwani S, Dorff TB, Stankevich E, Lowy I. Phase I trial of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.5004] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
48
|
Brahmer JR, Topalian S, Wollner I, Powderly JD, Picus J, Drake C, Covino J, Korman A, Pardoll D, Lowy I. Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.3006] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
49
|
Gerritsen W, van den Eertwegh AJ, de Gruijl T, van den Berg HP, Scheper RJ, Sacks N, Lowy I, Stankevich E, Hege K. Expanded phase I combination trial of GVAX immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHPRC). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.5146] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
50
|
Gerritsen WR, van den Eertwegh AJ, de Gruijl TD, Giaccone G, Scheper RJ, Sacks N, Harding T, Lowy I, Stankevich E, Hege K. Biochemical and immunologic correlates of clinical response in a combination trial of the GM-CSF-gene transduced allogeneic prostate cancer immunotherapy and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHRPC). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.5120] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5120 Background: A Phase 1 trial is underway to study the GM-CSF-secreting immunotherapy for prostate cancer (GVAX immunotherapy [GVAX IT]) and ipilimumab (ipi) in mHRPC patients (pts). Methods: Twelve pts were treated for 24 weeks (wks) with bi-weekly intradermal injections of GVAX IT and monthly Ipi. Pts were enrolled in cohorts of 3; each cohort received an escalating dose of ipi: 0.3, 1, 3 or 5 mg/kg. Results: Median follow-up is 15.0 months. All pts had GVAX IT injection site reactions. Five of six pts at the higher ipi doses (3 and 5 mg/kg) developed Grade 2 or 3 immune-related endocrinopathy, consistent with hypophysitis manifested by adrenal insufficiency and/or hypothyroidism, all successfully treated with standard hormone replacement. Two pts were tapered off Synthroid within 6 months (m). There was no induction of the alpha-21-hydroxylase auto-antibody that is seen in 90% of cases of auto-immune adrenal insufficiency. One pt in the 5 mg group developed a Grade 3 dose-limiting alveolitis. PSA responses (declines > 50%) were seen in 5/6 treated at the two higher ipi doses with median response duration of 4.9 m (2 on-going at 7.2 m and 12.8 m). These PSA responses were associated with immune-related endocrinopathy but were not consistently correlated with declines in adrenal androgens. One pt had resolution of measurable disease on abdominal CT scan. Immunomonitoring studies showed T cell and dendritic cell activation, more pronounced at higher doses. Biopsies of injection sites showed T cell infiltration. Multiple tumor-reactive antibodies (abs) induced by tx were identified by serologic analysis (SEREX), including abs to filamin B. Screening against 20 defined prostate cancer antigens demonstrated induction of abs to PSMA and NY-ESO-1. Conclusions: The GVAX IT and ipilimumab combination is active in mHRPC. There was an association between PSA response and immune-related adverse events. The PSA responses cannot be accounted for by adrenal insufficiency. The relationship between clinical activity and serologic response to identified antigens is under investigation. Tx of 16 additional pts is planned. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- W. R. Gerritsen
- VUMC Cancer Center, Amsterdam, The Netherlands; Cell Genesys Inc, South San Francisco, CA; Medarex, Inc., Bloomsbury, NJ
| | - A. J. van den Eertwegh
- VUMC Cancer Center, Amsterdam, The Netherlands; Cell Genesys Inc, South San Francisco, CA; Medarex, Inc., Bloomsbury, NJ
| | - T. D. de Gruijl
- VUMC Cancer Center, Amsterdam, The Netherlands; Cell Genesys Inc, South San Francisco, CA; Medarex, Inc., Bloomsbury, NJ
| | - G. Giaccone
- VUMC Cancer Center, Amsterdam, The Netherlands; Cell Genesys Inc, South San Francisco, CA; Medarex, Inc., Bloomsbury, NJ
| | - R. J. Scheper
- VUMC Cancer Center, Amsterdam, The Netherlands; Cell Genesys Inc, South San Francisco, CA; Medarex, Inc., Bloomsbury, NJ
| | - N. Sacks
- VUMC Cancer Center, Amsterdam, The Netherlands; Cell Genesys Inc, South San Francisco, CA; Medarex, Inc., Bloomsbury, NJ
| | - T. Harding
- VUMC Cancer Center, Amsterdam, The Netherlands; Cell Genesys Inc, South San Francisco, CA; Medarex, Inc., Bloomsbury, NJ
| | - I. Lowy
- VUMC Cancer Center, Amsterdam, The Netherlands; Cell Genesys Inc, South San Francisco, CA; Medarex, Inc., Bloomsbury, NJ
| | - E. Stankevich
- VUMC Cancer Center, Amsterdam, The Netherlands; Cell Genesys Inc, South San Francisco, CA; Medarex, Inc., Bloomsbury, NJ
| | - K. Hege
- VUMC Cancer Center, Amsterdam, The Netherlands; Cell Genesys Inc, South San Francisco, CA; Medarex, Inc., Bloomsbury, NJ
| |
Collapse
|